Free Trial

Nektar Therapeutics (NKTR) SEC Filings & 10K Form

Nektar Therapeutics logo
$0.75 -0.03 (-3.60%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$0.76 +0.01 (+1.06%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recent Nektar Therapeutics SEC Filings

DateFilerForm TypeView
04/17/2025
8:35 AM
BlackRock, Inc. (Filed by)
Nektar Therapeutics (Subject)
Form SCHEDULE 13G/A
04/15/2025
3:39 PM
Nektar Therapeutics (Filer)
Form PRE 14A
04/01/2025
11:15 PM
Nektar Therapeutics (Filer)
Form EFFECT
03/28/2025
3:22 PM
Nektar Therapeutics (Filer)
Form S-3
Registration statement under Securities Act of 1933  
03/14/2025
3:22 PM
Nektar Therapeutics (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
03/12/2025
3:20 PM
Nektar Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/24/2025
6:10 AM
Nektar Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/21/2025
5:04 PM
Nektar Therapeutics (Issuer)
ROBIN HOWARD W (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/21/2025
5:06 PM
Nektar Therapeutics (Issuer)
Wilson Mark Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/21/2025
5:07 PM
Nektar Therapeutics (Issuer)
Zalevsky Jonathan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2025
2:27 PM
Nektar Therapeutics (Subject)
Wilson Mark Andrew (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/19/2025
2:18 PM
Nektar Therapeutics (Subject)
Zalevsky Jonathan (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/19/2025
2:21 PM
Nektar Therapeutics (Subject)
ROBIN HOWARD W (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/14/2025
12:49 PM
Nektar Therapeutics (Subject)
SAMLYN CAPITAL, LLC (Filed by)
Form SCHEDULE 13G
02/14/2025
11:08 AM
EVENTIDE ASSET MANAGEMENT, LLC (Filed by)
Nektar Therapeutics (Subject)
Form SCHEDULE 13G/A
02/14/2025
7:43 AM
Deep Track Capital, LP (Filed by)
Nektar Therapeutics (Subject)
Form SCHEDULE 13G/A
01/17/2025
7:37 PM
GREER R SCOTT (Reporting)
Nektar Therapeutics (Issuer)
Form 5
Annual statement of changes in beneficial ownership of securities  
01/17/2025
7:39 PM
Nektar Therapeutics (Issuer)
WHITFIELD ROY A (Reporting)
Form 5
Annual statement of changes in beneficial ownership of securities  
01/17/2025
7:30 PM
Ajer Jeffrey Robert (Reporting)
Nektar Therapeutics (Issuer)
Form 5
Annual statement of changes in beneficial ownership of securities  
01/17/2025
7:32 PM
Brainard Diana (Reporting)
Nektar Therapeutics (Issuer)
Form 5
Annual statement of changes in beneficial ownership of securities  
01/17/2025
7:35 PM
CHESS ROBERT (Reporting)
Nektar Therapeutics (Issuer)
Form 5
Annual statement of changes in beneficial ownership of securities  
12/26/2024
6:04 PM
Nektar Therapeutics (Issuer)
Wilson Mark Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/26/2024
8:35 AM
Nektar Therapeutics (Subject)
Wilson Mark Andrew (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/23/2024
2:21 PM
Nektar Therapeutics (Subject)
Wilson Mark Andrew (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/20/2024
7:33 PM
Nektar Therapeutics (Issuer)
Zalevsky Jonathan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/19/2024
8:08 PM
Nektar Therapeutics (Issuer)
ROBIN HOWARD W (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/19/2024
2:12 PM
Nektar Therapeutics (Subject)
Zalevsky Jonathan (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/18/2024
3:17 PM
Nektar Therapeutics (Subject)
ROBIN HOWARD W (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/17/2024
7:54 PM
Nektar Therapeutics (Issuer)
ROBIN HOWARD W (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/17/2024
7:54 PM
Nektar Therapeutics (Issuer)
Wilson Mark Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/17/2024
7:55 PM
Nektar Therapeutics (Issuer)
Zalevsky Jonathan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/17/2024
2:29 PM
Nektar Therapeutics (Subject)
ROBIN HOWARD W (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/02/2024
8:24 AM
Nektar Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/20/2024
7:37 PM
Nektar Therapeutics (Issuer)
Zalevsky Jonathan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/20/2024
7:36 PM
Nektar Therapeutics (Issuer)
ROBIN HOWARD W (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/20/2024
7:36 PM
Nektar Therapeutics (Issuer)
Wilson Mark Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/19/2024
2:17 PM
Nektar Therapeutics (Subject)
ROBIN HOWARD W (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/19/2024
2:28 PM
Nektar Therapeutics (Subject)
Wilson Mark Andrew (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/14/2024
11:17 AM
EVENTIDE ASSET MANAGEMENT, LLC (Filed by)
Nektar Therapeutics (Subject)
Form SC 13G
11/14/2024
8:18 AM
Deep Track Capital, LP (Filed by)
Nektar Therapeutics (Subject)
Form SC 13G/A
11/08/2024
4:31 PM
BlackRock, Inc. (Filed by)
Nektar Therapeutics (Subject)
Form SC 13G
Silicon Valley Gold Rush (Ad)

A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.

Gates and Altman are betting big—see why
11/07/2024
3:31 PM
Nektar Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/04/2024
7:52 AM
Nektar Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/20/2024
8:15 PM
Nektar Therapeutics (Issuer)
Wilson Mark Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/20/2024
8:15 PM
Nektar Therapeutics (Issuer)
Zalevsky Jonathan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/20/2024
8:14 PM
Nektar Therapeutics (Issuer)
ROBIN HOWARD W (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/19/2024
3:13 PM
Nektar Therapeutics (Subject)
Wilson Mark Andrew (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/19/2024
2:45 PM
Nektar Therapeutics (Subject)
Zalevsky Jonathan (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/14/2024
5:02 PM
CHESS ROBERT (Reporting)
Nektar Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/05/2024
11:15 PM
Nektar Therapeutics (Filer)
Form EFFECT
06/05/2024
4:30 PM
Nektar Therapeutics (Filer)
Form 424B3
05/28/2024
3:51 PM
Nektar Therapeutics (Filer)
Form S-3
Registration statement under Securities Act of 1933  
05/20/2024
8:12 PM
Nektar Therapeutics (Issuer)
Wilson Mark Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/20/2024
8:13 PM
Nektar Therapeutics (Issuer)
Zalevsky Jonathan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/20/2024
8:14 PM
Nektar Therapeutics (Issuer)
ROBIN HOWARD W (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/13/2024
3:36 PM
Deep Track Biotechnology Master Fund, Ltd. (Reporting)
Deep Track Capital, LP (Reporting)
KROIN DAVID (Reporting)
Nektar Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/09/2024
3:20 PM
Nektar Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:NKTR) was last updated on 5/5/2025 by MarketBeat.com Staff
From Our Partners